Classical Hematology Program

Smilow Cancer Hospital at North Haven

6 Devine Street

North Haven, CT 06473

Directions

1 of 2

Classical Hematology Program
Smilow Cancer Hospital at North Haven
6 Devine Street
North Haven, CT 06473
- Directions
Park Avenue Medical Center
5520 Park Avenue
Trumbull, CT 06611
- Directions

EDIT PROFILE

View Academic Profile

Click here to view more about this specialist's research and educational efforts on https://medicine.yale.edu

Click here to view more about this specialist's research and educational efforts onhttps://medicine.yale.edu

Anna Kress, MD

Hematology, Hematologic Oncology

Telehealth is available

Learn more about telehealth

Patient type treated

Adult

Accepting new patients

Yes

Referral required

Not Applicable

Board Certified in

Internal Medicine and Hematology (Internal Medicine)

Insurance accepted

View Academic Profile

Click here to view more about this specialist's research and educational efforts on https://medicine.yale.edu

Click here to view more about this specialist's research and educational efforts onhttps://medicine.yale.edu

Biography

Anna Kress, MD, is a medical oncologist and hematologist who cares for people with B-cell lymphomas (cancers that affect specific white blood cells) and nonmalignant blood disorders.

As an assistant professor of medicine (hematology) at Yale School of Medicine, Dr. Kress research focused on advancing treatments for lymphomas and blood diseases.

Dr. Kress received her medical degree from Columbia University Vagelos College of Physicians and Surgeons, then completed her internship and residency in internal medicine at Columbia University Medical Center, NewYork-Presbyterian Hospital. She later pursued a fellowship in medical oncology and hematology at Yale New Haven Hospital.

Titles

Assistant Professor of Medicine (Hematology)

Education & Training

Internal Medicine Resident
Columbia University, New York Presbyterian Hospital (2019)
MD
Columbia University, College of P&S (2016)
BA
Cornell University (2010)

Additional Information

Board Certifications

Publications

High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Farooq U, Saad M, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Advances 2023, 7: 6381-6394. PMID: 37171397, PMCID: PMC10598493, DOI: 10.1182/bloodadvances.2023009731.
Warm autoantibodies mimicking alloantibodies: Three cases of autoantibodies with unusual antigenic specificity
Jacobs J, Binns T, Abels E, Campos J, Elkabbani R, Kress A, Sostin N, Tormey C. Warm autoantibodies mimicking alloantibodies: Three cases of autoantibodies with unusual antigenic specificity. American Journal Of Clinical Pathology 2023, 160: 561-565. PMID: 37598315, DOI: 10.1093/ajcp/aqad095.
Postibrutinib relapse outcomes for patients with marginal zone lymphoma
Epperla N, Zhao Q, Chowdhury S, Shea L, Moyo T, Reddy N, Sheets J, Weiner DM, Geethakumari P, Kandarpa M, Bruno X, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover N, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Postibrutinib relapse outcomes for patients with marginal zone lymphoma. Blood Advances 2022, 7: 88-91. PMID: 36269847, PMCID: PMC9827027, DOI: 10.1182/bloodadvances.2022008634.
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. Journal Of Hematology & Oncology 2022, 15: 96. PMID: 35842643, PMCID: PMC9287914, DOI: 10.1186/s13045-022-01316-1.
Therapeutic Options for Aggressive T-Cell Lymphomas.
Lue JK, Kress A, Amengual JE. Therapeutic Options for Aggressive T-Cell Lymphomas. Current Hematologic Malignancy Reports 2017, 12: 269-281. PMID: 28573497, DOI: 10.1007/s11899-017-0389-7.

Departments and Programs

Locations

Classical Hematology Program

Smilow Cancer Hospital at North Haven

6 Devine Street

North Haven, CT 06473

Directions

1 of 2

Classical Hematology Program
Smilow Cancer Hospital at North Haven
6 Devine Street
North Haven, CT 06473
- Directions
Park Avenue Medical Center
5520 Park Avenue
Trumbull, CT 06611
- Directions

View Academic Profile

Click here to view more about this specialist's research and educational efforts on https://medicine.yale.edu

Click here to view more about this specialist's research and educational efforts onhttps://medicine.yale.edu

Biography

Anna Kress, MD, is a medical oncologist and hematologist who cares for people with B-cell lymphomas (cancers that affect specific white blood cells) and nonmalignant blood disorders.

As an assistant professor of medicine (hematology) at Yale School of Medicine, Dr. Kress research focused on advancing treatments for lymphomas and blood diseases.

Titles

Assistant Professor of Medicine (Hematology)

Education & Training

Internal Medicine Resident
Columbia University, New York Presbyterian Hospital (2019)
MD
Columbia University, College of P&S (2016)
BA
Cornell University (2010)

Additional Information

Board Certifications

Publications

High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Farooq U, Saad M, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Advances 2023, 7: 6381-6394. PMID: 37171397, PMCID: PMC10598493, DOI: 10.1182/bloodadvances.2023009731.
Warm autoantibodies mimicking alloantibodies: Three cases of autoantibodies with unusual antigenic specificity
Jacobs J, Binns T, Abels E, Campos J, Elkabbani R, Kress A, Sostin N, Tormey C. Warm autoantibodies mimicking alloantibodies: Three cases of autoantibodies with unusual antigenic specificity. American Journal Of Clinical Pathology 2023, 160: 561-565. PMID: 37598315, DOI: 10.1093/ajcp/aqad095.
Postibrutinib relapse outcomes for patients with marginal zone lymphoma
Epperla N, Zhao Q, Chowdhury S, Shea L, Moyo T, Reddy N, Sheets J, Weiner DM, Geethakumari P, Kandarpa M, Bruno X, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover N, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Postibrutinib relapse outcomes for patients with marginal zone lymphoma. Blood Advances 2022, 7: 88-91. PMID: 36269847, PMCID: PMC9827027, DOI: 10.1182/bloodadvances.2022008634.
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. Journal Of Hematology & Oncology 2022, 15: 96. PMID: 35842643, PMCID: PMC9287914, DOI: 10.1186/s13045-022-01316-1.
Therapeutic Options for Aggressive T-Cell Lymphomas.
Lue JK, Kress A, Amengual JE. Therapeutic Options for Aggressive T-Cell Lymphomas. Current Hematologic Malignancy Reports 2017, 12: 269-281. PMID: 28573497, DOI: 10.1007/s11899-017-0389-7.

Departments and Programs

Locations

Classical Hematology Program

Smilow Cancer Hospital at North Haven

6 Devine Street

North Haven, CT 06473

Directions

1 of 2

Classical Hematology Program
Smilow Cancer Hospital at North Haven
6 Devine Street
North Haven, CT 06473
- Directions
Park Avenue Medical Center
5520 Park Avenue
Trumbull, CT 06611
- Directions

Classical Hematology Program

Smilow Cancer Hospital at North Haven

6 Devine Street

North Haven, CT 06473

Directions

1 of 2

Classical Hematology Program
Smilow Cancer Hospital at North Haven
6 Devine Street
North Haven, CT 06473
- Directions
Park Avenue Medical Center
5520 Park Avenue
Trumbull, CT 06611
- Directions

EDIT PROFILE